Bifogade filer
From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system
Kurs
+6,33%
Likviditet
1,78 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-10-29 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-16 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2026-05-19 | - | Årsstämma |
| 2026-04-22 | - | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | - | Bokslutskommuniké 2025 |
| 2025-10-29 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-30 | - | Extra Bolagsstämma 2025 |
| 2025-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2025-05-19 | - | Årsstämma |
| 2025-04-22 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-17 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-23 | - | Extra Bolagsstämma 2024 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Extra Bolagsstämma 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-20 | - | Bokslutskommuniké 2022 |
| 2023-02-16 | - | Extra Bolagsstämma 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-05 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-05 | - | Extra Bolagsstämma 2018 |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-28 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-15 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Årsstämma |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-17 | - | Extra Bolagsstämma 2016 |
| 2016-04-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2016-04-27 | - | Årsstämma |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-24 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2015-05-19 | - | Årsstämma |
| 2015-05-19 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-25 | - | Bokslutskommuniké 2014 |
| 2014-11-27 | - | Kvartalsrapport 2014-Q3 |
| 2014-11-21 | - | Extra Bolagsstämma 2014 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2014-05-14 | - | Årsstämma |
| 2014-05-14 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-27 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-16 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2013-05-15 | - | Årsstämma |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-28 | - | Bokslutskommuniké 2012 |
| 2013-01-08 | - | Extra Bolagsstämma 2013 |
| 2012-11-21 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2012-05-23 | - | Årsstämma |
| 2012-05-23 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-23 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-23 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-27 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2011-05-26 | - | Årsstämma |
| 2011-05-26 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-16 | - | Bokslutskommuniké 2010 |
| 2010-11-24 | - | Kvartalsrapport 2010-Q3 |
| 2010-05-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2010-05-27 | - | Kvartalsrapport 2010-Q1 |
| 2009-11-25 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
UPPSALA, Sweden – Senzime AB today announced that its TetraGraph® neuromuscular monitoring system has received an additional FDA Class II 510(k) clearance. The new FDA clearance follows submission in April 2026 and expands the system’s capabilities, further strengthening the TetraGraph’s competitive advantages.
The new 510(k) clearance includes, among other things, unique capabilities of the next-generation TetraGraph system, and additional innovations that will be introduced over time.
“This FDA clearance is an important milestone for Senzime, enabling broadened competitive advantages of current and future capabilities of the TetraGraph system,” said Philip Siberg, CEO of Senzime. “We continue to pioneer our industry by developing innovations that enhance patient safety, improve clinical workflows, and support more cost-effective care.”
The TetraGraph system is used by anesthesiologists in more than 750 hospitals worldwide to support patient safety during and after surgery. The system uses proprietary algorithms and advanced sensors to accurately monitor neuromuscular function during surgery. This helps clinicians to determine when it is appropriate to intubate patients, optimize dosing of neuromuscular blocking and reversal agents, and assess when patients are ready for extubation and spontaneous breathing after surgery.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.
Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.